In this Section
168393 Evaluating a Multiple Morbidities Testing Program Using the Behavioral Risk Group (BRG) Model
Monday, October 27, 2008: 2:30 PM
Background: The integration of HIV testing with hepatitis and sexually transmitted infection testing has been advocated as a best practice for public health.
Methods: Data from a Los Angeles County--funded multiple morbidities testing program (HIV, hepatitis, STIs) were analyzed for 2005-2007. Data are compiled by behavioral risk group (BRG).
Results: 2011 test results were analyzed using analysis of variance. A significant overall model (F(35,1729)=3.13,p<.0001) for number of tests accessed by BRG and racial/ethnic groups was found. There was a significant main effect of BRG (F=11.21,p=.0001) but no effect of race/ethnicity and no interaction. Transgenders (M=6.77, SD=.44) and men-who-have-sex-with-men/injection drug users (MSM/IDUs) (M=6.39, SD=2.99) had the highest mean number of tests accessed. Native Americans accessed the fewest number of tests (M=4.52, SD=2.82) but this was not statistically significant. There was also a significant overall model for the total number of positive test results by BRG and racial/ethnic group (F(35,1729)=7.87p<.0001; this model had significant main effects of BRG (F=31.87,p<.0001) and racial/ethnic group (F=3.32,p=.0002) as well as a significant interaction of BRG and racial ethnic group (F=2.50,p<.0001). MSM-IDUs had the highest mean number of infections (M=1.44, SD=1.46) compared to other BRGs, and Native Americans had the highest mean number of infections among racial/ethnic groups (M.81, SD=.98).
Results: Multiple morbidities testing which targets BRGs appears to be working overall. Changes to this approach may be needed to include racial/ethnic groups with high levels of positive test results and low levels of utilization, such as Native Americans.
Presenting author's disclosure statement:
Qualified on the content I am responsible for because: I performed all data analysis, assisted with the interpretation of results, and wrote the abstract.
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.